Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 7/20 | 1.00 |
| ▸ | TERT | O14746 | 7/20 | 0.85 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.78 |
| ▸ | CASP1 | P29466 | 1/20 | 0.78 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.78 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.78 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.78 |
| ▸ | CCR6 | P51684 | 1/20 | 0.78 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.78 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.78 |
| ▸ | PRDX1 | Q06830 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18782082 | 0.92 | NR4A1 (0.85) | NR4A1TERTPTPN1CASP1ABHD6 | |
| SCHEMBL24927429 | 0.92 | TERT (1.00) | NR4A1TERTPTPN1CASP1ABHD6 | |
| SCHEMBL19733508 | 0.92 | TERT (1.00) | NR4A1TERTPTPN1CASP1ABHD6 | |
| SCHEMBL18781794 | 0.92 | NR4A1 (0.84) | NR4A1TERTPTPN1CASP1ABHD6 | |
| SCHEMBL13943187 | 0.91 | NR4A1 (1.00) | NR4A1TERTPTPN1CASP1ABHD6 | |
| SCHEMBL19733643 | 0.91 | NR4A1 (0.87) | NR4A1TERTPTPN1CASP1ABHD6 | |
| SCHEMBL13944038 | 0.91 | NR4A1 (1.00) | NR4A1TERTPTPN1CASP1ABHD6 | |
| SCHEMBL12462656 | 0.91 | NR4A1 (1.00) | NR4A1TERTPTPN1CASP1ABHD6 | |
| SCHEMBL20371742 | 0.90 | NR4A1 (0.82) | NR4A1TERTPTPN1CASP1ABHD6 | |
| SCHEMBL12462879 | 0.90 | NR4A1 (0.84) | NR4A1TERTPTPN1CASP1ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753436-B2 | Analogs of celastrol | ERX PHARMACEUTICALS CORPORATION (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753436-B2 | Analogs of celastrol | ERX PHARMACEUTICALS CORPORATION (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210061851-A1 | ANALOGS OF CELASTROL | ERX PHARMACEUTICALS CORPORATION | 2021-03-04 | — | — | US | disclosed |
| US-10662218-B2 | Analogs of celastrol | ERX PHARMACEUTICALS CORPORATION | 2020-05-26 | — | — | US | disclosed |
| US-20180194709-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2018-07-12 | — | — | US | disclosed |
| US-20180194709-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2018-07-12 | — | — | US | disclosed |
| WO-2017070615-A1 | ANALOGS OF CELASTROL | ERX PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20150274634-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2015-10-01 | — | — | US | disclosed |
| WO-2015148802-A1 | CELASTROL AND DERIVATIVES FOR THE TREATMENT OF OBESITY | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-10-01 | — | — | WO | disclosed |
| US-20150274634-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061851-A1 | ANALOGS OF CELASTROL | GIPR, GPR119, EBP | NR4A1 1945/4885TERT 3225/4885PTPN1 4495/4885 |
| US-20180194709-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF | GPR119, FABP4, ADIPOR1 | NR4A1 2631/4885TERT 3318/4885PTPN1 1328/4885 |
| US-20150274634-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF | GPR119, FABP4, ADIPOR1 | NR4A1 2631/4885TERT 3318/4885PTPN1 1328/4885 |
| US-10662218-B2 | Analogs of celastrol | GIPR, GPR119, EBP | NR4A1 1945/4885TERT 3225/4885PTPN1 4495/4885 |
| US-11753436-B2 | Analogs of celastrol | GIPR, GPR119, EBP | NR4A1 1945/4885TERT 3225/4885PTPN1 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.